Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 /
G蛋白偶联受体/G蛋白
免疫/炎症
/ CXCR / LY2510924

LY2510924 {[allProObj[0].p_purity_real_show]}

货号：A560023

LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, LY2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation.

LY2510924 化学结构 CAS号：1088715-84-7
LY2510924 化学结构
CAS号：1088715-84-7
LY2510924 3D分子结构
CAS号：1088715-84-7
LY2510924 化学结构 CAS号：1088715-84-7
LY2510924 3D分子结构 CAS号：1088715-84-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

LY2510924 纯度/质量文件 产品仅供科研

货号：A560023 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

更多 >
产品名称 CXCR1 ↓ CXCR2 ↓ CXCR4 ↓ 其他靶点 纯度
Reparixin ✔ 99%+
SB225002 +++

CXCR2, IC50: 22 nM

 		99%+
Plerixafor ++

CXCR4, IC50: 44 nM

 		99%
AMD 3465 6HBr ✔ 98%
WZ811 ++++

CXCR4, EC50: 0.3 nM

 		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

LY2510924 生物活性

描述 Through binding with CC- and CXC-chemokines, CCR and CXCR, the subsets of the chemokine receptor family can trigger an intracellular signal transduction cascade, thus mediating the recruitment of immune cells to the inflammation or infection sites and implicated in several immuno-related disease states, organogenesis, angiogenesis and tumor growth and metastasis. LY2510924 is a potent and selective CXCR4 inhibitor with IC50 value of 0.079nM for blocking SDF-1α binding to CXCR4. LY2510924 could completely inhibit SDF-1-mediated GTP binding with Kb value of 0.38nM. Selective inhibition by LY2510924 of SDF-1-induced migration of U937 cells can be achieved in a concentration-dependent manner with IC50 of 0.26nM. As prediction, the SDF-1- and CXCR4-mediated cell signaling, including p-ERK and p-AKT, can be inhibited by LY2510924 at concentration of 3.3nM and 0.33nM in HeLa cells, as well as IC50 values of 1.4 and 1.2nM, respectively, in Namalwa cells expressing high level of CXCR4. Subcutaneous injection with 3mg/kg LY2510924, BID, for 7 days, significantly inhibit the tumor growth of an NHL Namalwa xenograft model. Antitumor growth activities of LY2510924 can be also observed at dose of 2mg/kg or 5mg/kg in solid cancer xenograft models, RCC A-498 and A549 xenografts. Subcutaneous injection with 3mg/kg LY2510924 twice daily for 13 or 15 days inhibited breast cancer metastasis in the MDA-MB-231 model due to blocking migration/homing process of tumor cells to reduce the colony numbers of lung metastasis, as well as inhibiting cell proliferation to reduce the size of the colonies after tumor cell homing to the lung[1].
作用机制 LY2510924 can occupy the binding pocket and possess ligand-receptor interactions with CXCR4 residues.[1]

LY2510924 动物研究

Dose Mice: 0.06 mg/kg - 5 mg/kg[2] (s.c.)
Administration s.c.

LY2510924 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01439568 Extensive Stage Small Cell Lun... 展开 >>g Carcinoma 收起 << Phase 2 Completed - United States, Colorado ... 展开 >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Denver, Colorado, United States, 80218 United States, Florida For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fort Myers, Florida, United States, 33916 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Orlando, Florida, United States, 32804 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Pensacola, Florida, United States, 32503 United States, Illinois For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chicago, Illinois, United States, 60637 United States, Maryland For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bethesda, Maryland, United States, 20817 United States, Missouri For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Springfield, Missouri, United States, 65804 United States, Nebraska For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Omaha, Nebraska, United States, 68114 United States, Ohio For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Cincinnati, Ohio, United States, 45242 United States, South Carolina For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Greenville, South Carolina, United States, 29605 United States, Tennessee For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chattanooga, Tennessee, United States, 37404 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Memphis, Tennessee, United States, 38120 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nashville, Tennessee, United States, 37203 United States, Texas For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fort Worth, Texas, United States, 76104 United States, Virginia For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Richmond, Virginia, United States, 23230 收起 <<
NCT01391130 Metastatic Clear Cell Renal Ce... 展开 >>ll Carcinoma 收起 << Phase 2 Terminated(Study Terminated du... 展开 >>e to Insufficient Efficacy) 收起 << - -
NCT02737072 Solid Tumor Phase 1 Terminated - -

LY2510924 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.84mL

0.17mL

0.08mL

4.20mL

0.84mL

0.42mL

8.41mL

1.68mL

0.84mL

LY2510924 技术信息

CAS号1088715-84-7
分子式C62H88N14O10
分子量 1189.45
SMILES Code O=C(NCC(N[C@@H](C(N[C@H](C(N)=O)CCCCNC(C)C)=O)CCC1=O)=O)[C@@H](NC([C@@]([H])(CCCNC(N)=N)NC([C@H](CCCCNC(C)C)NC([C@]([H])(CC2=CC=C(O)C=C2)NC([C@H](CC3=CC=CC=C3)N1)=O)=O)=O)=O)CC4=CC5=C(C=C4)C=CC=C5
MDL No. MFCD30537218
别名
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C
溶解方案 请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案一
方案二

Tags: LY2510924 | 1088715-84-7 | LY 2510924 | LY-2510924 | CXCR Inhibitor | GPCR/G Protein | Immunology/Inflammation | CXCR | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | LY2510924 纯度/质量文件 | LY2510924 亚型比较 | LY2510924 生物活性 | LY2510924 动物研究 | LY2510924 临床数据 | LY2510924 实验方案 | LY2510924 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z